Slide 1: Half Year 2024 Results
Formycon AG Half Year 2024 Results August 13, 2024 15:00 (CEST)
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial si
Slide 3: Maximizing our assets along a clear path
Laser focus on pipeline execution and expansion Maximizing our assets along a clear path 2023 2024 Strong financial Important year Sustainable and operational to prepare the profitability with performance ground for the continuous pipeline next ignition growth stage 3 Formycon AG — H1 2024
Slide 4: Highlights H1/2024
Biosimilar Development HIGHLIGHTS H1/2024 4 Formycon AG — H1 2024
Slide 5: Launched & late-stage Projects well on track – Strong Newsflow ahead
Launched & late-stage Projects well on track – Strong Newsflow ahead Lucentis® Biosimilar Stelara® Biosimilar Candidate Eylea® Biosimilar Candidate [Ranibizumab] [Ustekinumab] [Aflibercept] ● Launch in Canada and Switzerland ● Settlement for Launch in Europe ● FDA Approval for FYB203/ by Teva. and C
Slide 6: Strong FYB201 Performance across the world
Strong FYB201 Performance across the world FYB201 is so far launched in 19 countries UK Marketshare: 79%* US Marketshare: 45%* FYB201 launched Further potential *Volume-based · Source: IQVIA Monthly Data R3M (rolling 3-month) Cimerli® is a registered trademark of Coherus Biosciences Inc. · Ongavia®
Slide 7: 2nd wave of Projects progressing well
2nd wave of Projects progressing well Keytruda® Biosimilar Candidate Undisclosed New biosimilar candidate [Pembrolizumab] Biosimilar Candidates in selection process ● First patient entered Phase I ● Clones with superior stability, ● Selection process initiated along clinical trial “Dahlia” to compar
Slide 8: Financial Performance – H1/2024
Financial Position FINANCIAL PERFORMANCE – H1/2024 8 Formycon AG — H1 2024
Slide 9: Profit & Loss fully on track
Profit & Loss fully on track 1H 2024 vs. 1H 2023 – Financials in expected range In € million 1H 2024 1H 2023 Change in % Comment H1/2023 included 10m Upfront Fresenius Kabi Sales 26.9 43.8 -39% Decreasing development services as anticipated H1/2024 Higher royalty income FYB201 Cost of Sales -25.0 -2
Slide 10: Group asset Structure as of Jun. 30, 2024 vs. Dec. 31, 2023
Group asset Structure as of Jun. 30, 2024 vs. Dec. 31, 2023 Balance Sheet total Equity Liabilities € 947.8 million € 576.3 million € 371.5 million + € 57.4 million + € 73.6 million - € 16.1 million +6% +15% -4% Equity Ratio Non-current assets vs. Cash & Cash Equivalents Total equity and liabilities
Slide 11: Cash-Flows and Working Capital
Cash-Flows and Working Capital 1H 2024 In € million 1H 2024 Remarks Working Capital June 30, 2024 • -16.9m EBITDA Net cash from operating • -12.2m contract assets Cash and cash equivalents 40.6 -31.2 activities FYB202 • Remainder other WC Current receivables 10.6 • Development costs FYB206 - Net cas
Slide 12: Outlook 2024 – Prepare the Ground
Financial Position O U T L O O K 2 0 2 4 – P R E PA R E T H E G R O U N D 12 Formycon AG — H1 2024
Slide 13: 2024 Guidance raised for adjusted EBITDA & Working Capital
2024 Guidance raised for adjusted EBITDA & Working Capital Fiscal Revenue EBITDA Adjusted EBITDA* Working Capital Guidance 2024: year 2024 updated − Revenue: Unchanged forecast 55 to 65 -25 to -15 -5 to +5 35 to 45 − EBITDA: Unchanged € million € million € million € million − Adjusted EBITDA: Raised
Slide 14: Formycon on the stock market
Formycon on the stock market − Listed on Frankfurt Stock Exchange since June 2012 / Shareholder Structure SME segment “Scale” (Open Market) ● ~58 % Anchor Investors incl. Athos KG, − Registered capital: € 17,656,902 Active Ownership Capital, Wendeln & Cie. KG, Shares outstanding: 17,656,902 (w/o par
Slide 15: Exciting newsflow expected in the next months
Exciting newsflow expected in the next 9 months “First Patient In” Phase I “First Patient In” Phase III Approval of Positive CHMP Opinion clinical trial of Keytruda® clinical trial of Keytruda® Eylea® Biosimilar- for Stelara® Biosimilar- Biosimilar-Candidate Biosimilar-Candidate Candidate Candidate
Slide 16: Fully focused pure-play Biosimilar Company
Fully focused pure-play Biosimilar Company WE HAVE all ingredients to successfully WE ACT in a highly attractive market develop and commercialize a growing pipeline WE CREATED a strong Platform with WE ARE entering the next stage of the track record Formycon Growth Story 16 Formycon AG — H1 2024
Slide 17: We are happy to answer your questions
Formycon AG WE ARE HAPPY TO ANSWER YO U R Q U E S T I O N S www.formycon.com 17 Formycon AG — H1 2024